Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases

被引：0
|
作者：
Siddharth Singh
Herbert C. Heien
Lindsey Sangaralingham
Nilay D. Shah
William J. Sandborn
机构：
[1] University of California San Diego,Division of Gastroenterology, Department of Medicine
[2] University of California San Diego,Division of Biomedical Informatics, Department of Medicine
[3] Mayo Clinic,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
[4] Mayo Clinic,Division of Health Care Policy and Research, Department of Health Services Research
来源：
Digestive Diseases and Sciences | 2022年 / 67卷
关键词：
Cancer; Safety; Choice; Colitis; Biologics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2510 / 2516
页数：6
相关论文
共 50 条
  • [21] CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY ASSOCIATED WITH TUMOR NECROSIS FACTOR-α ANTAGONISTS
    Alshekhlee, Amer
    Basiri, Kevian
    Miles, J. Douglas
    Ahmad, Saef A.
    Katirji, Bashar
    MUSCLE & NERVE, 2010, 41 (05) : 723 - 727
  • [22] Tumor necrosis factor-α inhibitor use in patients with malignancy: is it safe?
    Oh, Gyu Man
    Moon, Won
    INTESTINAL RESEARCH, 2020, 18 (03) : 245 - 246
  • [23] Tumor Necrosis Factor-α Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies A Controlled Study
    Angel, Kristin
    Provan, Sella Aarrestad
    Gulseth, Hanne Lovdahl
    Mowinckel, Petter
    Kvien, Tore Kristian
    Atar, Dan
    HYPERTENSION, 2010, 55 (02) : 333 - 338
  • [24] Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
    Gareb, Bahez
    Otten, Antonius T.
    Frijlink, Henderik W.
    Dijkstra, Gerard
    Kosterink, Jos G. W.
    PHARMACEUTICS, 2020, 12 (06) : 1 - 31
  • [25] Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey
    Oussalah, A.
    Roblin, X.
    Laharie, D.
    Filippi, J.
    Flamant, M.
    Faure, P.
    Phelip, J. -M.
    Bigard, M. -A.
    Peyrin-Biroulet, L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (08) : 854 - 863
  • [26] Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases
    Bank, Steffen
    Andersen, Paal Skytt
    Burisch, Johan
    Pedersen, Natalia
    Roug, Stine
    Galsgaard, Julie
    Turino, Stine Ydegaard
    Brodersen, Jacob Broder
    Rashid, Shaista
    Avlund, Sara
    Olesen, Thomas Bastholm
    Green, Anders
    Hoffmann, Hans Jurgen
    Thomsen, Marianne Kragh
    Thomsen, Vibeke Ostergaard
    Nexo, Bjorn Andersen
    Vogel, Ulla
    Andersen, Vibeke
    DANISH MEDICAL JOURNAL, 2015, 62 (03):
  • [27] Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab
    Chiorean, Michael
    Afzali, Anita
    Cross, Raymond K.
    Macaulay, Dendy
    Griffith, Jenny
    Wang, Anthony
    Garcia-Horton, Viviana
    CROHNS & COLITIS 360, 2020, 2 (02)
  • [28] A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists
    Townsend, Cassandra M.
    Khanna, Reena
    Wilson, Aze Suzanne
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (12) : 4436 - 4440
  • [29] A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists
    Cassandra M. Townsend
    Reena Khanna
    Aze Suzanne Wilson
    Digestive Diseases and Sciences, 2021, 66 : 4436 - 4440
  • [30] Infections associated with tumor necrosis factor-α antagonists
    Crum, NF
    Lederman, ER
    Wallace, MR
    MEDICINE, 2005, 84 (05) : 291 - 302
12345